Figure 1: Flowchart of randomization of 1.529 patients attended at HSPE
Baseline characteristics |
HCQ Group |
Placebo Group |
p |
Sex male |
19 (57,5) |
20 (66,6) |
0,46 |
Age (mean; years) |
60 |
59 |
0,85 |
Comorbidities |
23 (69,6) |
24 (80) |
0,35 |
Inclusion criteria |
33 (100) |
30 (100) |
0,12 |
Symptoms of acute respiratory infection |
36,5 (35,5-39,1) |
36,7 (35,9-38,6) |
0,40 |
Laboratory measurements |
13.6 (10,1-19,3) |
13.7 (9.4-16.9) |
0,88 |
Table 1: Baseline characteristics of the patients by group
COPD = chronic obstructive pulmonary disease; CT = computed tomography; AST = aspartate aminotransferase; ALT = alanine aminotransferase; LDH = lactic dehydrogenase; IQR = interquartile range; bpm = breath per minute
D5 characteristics |
HCQ Group |
Placebo Group |
p |
Symptoms of acute respiratory infection |
36,5 (35,8-38) |
36,6 (35,4-38,9) |
0,78 |
Table 2: Signs of patient’s severity on D5 of study
bpm=breath per minute
Outcome |
HCQ Group |
Placebo Group |
p |
Mechanical ventilation |
8 (24,2) |
6 (20) |
0,68 |
Death |
4 (12,1) |
2 (6,6) |
0,46 |
Adverse events |
|
|
|
Increase in hepatic transaminases |
1 (3) |
0 (0) |
0,34 |
QTc interval prolongation |
0 (0) |
0 (0) |
|
Table 3: Comparison of outcomes and adverse events of patients randomized to the study
Corrected QT interval (mean, ms) |
D0 |
D3 |
D5 |
HCQ (N=33) |
396 |
406 |
402 |
Placebo (N=30) |
382 |
386 |
398 |
Table 4: Corrected QT interval in both groups on D0, D3 and D5 of study
ms= milliseconds
Tables at a glance
Figures at a glance